NOVO.B.DK

358.3

+2.64%↑

COLO.B.DK

616

-0.06%↓

HLUNB.DK

42.4

-0.75%↓

ZEAL.DK

432.6

+5.44%↑

AMBUB.DK

98.65

+2.12%↑

NOVO.B.DK

358.3

+2.64%↑

COLO.B.DK

616

-0.06%↓

HLUNB.DK

42.4

-0.75%↓

ZEAL.DK

432.6

+5.44%↑

AMBUB.DK

98.65

+2.12%↑

NOVO.B.DK

358.3

+2.64%↑

COLO.B.DK

616

-0.06%↓

HLUNB.DK

42.4

-0.75%↓

ZEAL.DK

432.6

+5.44%↑

AMBUB.DK

98.65

+2.12%↑

NOVO.B.DK

358.3

+2.64%↑

COLO.B.DK

616

-0.06%↓

HLUNB.DK

42.4

-0.75%↓

ZEAL.DK

432.6

+5.44%↑

AMBUB.DK

98.65

+2.12%↑

NOVO.B.DK

358.3

+2.64%↑

COLO.B.DK

616

-0.06%↓

HLUNB.DK

42.4

-0.75%↓

ZEAL.DK

432.6

+5.44%↑

AMBUB.DK

98.65

+2.12%↑

Search

Genmab A-S

Open

1,787.5 -0.69

Overview

Share price change

24h

Current

Min

1768.5

Max

1800

Key metrics

By Trading Economics

Income

228M

423M

Sales

210M

925M

P/E

Sector Avg

14.144

35.664

EPS

34.77

Profit margin

45.73

Employees

2,639

EBITDA

-1.4B

448M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-1.49% downside

Market Stats

By TradingEconomics

Market Cap

21B

108B

Previous open

1788.19

Previous close

1787.5

Genmab A-S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sie 2025, 15:10 UTC

Major Market Movers

Genmab Shares Rise After Positive Results for Epcoritamab Trial

10 mar 2025, 15:16 UTC

Major Market Movers

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 gru 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Comparison

Price change

Genmab A-S Forecast

Price Target

By TipRanks

-1.49% downside

12 Months Forecast

Average 2,493.35 DKK  -1.49%

High 3,320 DKK

Low 308.417 DKK

Based on 7 Wall Street analysts offering 12 month price targets forGenmab A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

7 ratings

3

Buy

2

Hold

2

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat